Herpes simplex glycoprotein vaccine - Chiron

Drug Profile

Herpes simplex glycoprotein vaccine - Chiron

Alternative Names: HSV-2 gB2/gD2/MF59 vaccine - Chiron; Two-component gB2 and gD2 recombinant glycoproteins subunit vaccine - Chiron

Latest Information Update: 22 Aug 2008

Price : $50

At a glance

  • Originator Chiron Corporation
  • Class Synthetic vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Herpes simplex virus infections

Most Recent Events

  • 20 Apr 2006 Chiron Corporation has been acquired and merged into Novartis
  • 28 May 2002 Ventiv Health France will market Chiron's vaccines product line in France
  • 08 Feb 2000 A study has been added to the Viral Infections therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top